



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Corti et al

Examiner: To Be Assigned

Art Unit: 1614

Application No.: **10/622,817**

Filed: **July 18, 2003**

Title: **METHOD FOR DETERMINING THE
ABILITY OF A COMPOUND TO MODIFY
THE INTERACTION BETWEEN PARKIN
AND THE p38 PROTEIN**

I hereby certify that this correspondence is being
deposited with the United States Postal Service as First
Class Mail in an envelope addressed to Mail Stop
Missing Parts, Commissioner for Patents, P.O. Box
1450, Alexandria, VA 22313-1450, on

March 19, 2004
Date of Deposit

Debi Congher
Signature

**STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE
COPIES PURSUANT TO 37 C.F.R. 1.821 (f)**

Mail Stop Missing Parts
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the enclosed substitute pages of the "Sequence Listing" and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same; and (2) the content of the substitute copy of the Sequence Listing and the computer readable copies required by 37 C.F.R. 1.821 (e) contain no new matter. Support for the Amendments can be found in the application as filed.

Respectfully submitted,

Michael J. Schmelzer, Reg. No. 43,093
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-4797
Telefax (908) 231-2626

Docket No. FRAV2002/0020US NP